Alpha Tau Medical Ltd. (DRTS)
| Market Cap | 882.74M +298.8% |
| Revenue (ttm) | n/a |
| Net Income | -42.63M |
| EPS | -0.53 |
| Shares Out | 88.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 939,450 |
| Open | 10.65 |
| Previous Close | 10.36 |
| Day's Range | 9.77 - 10.77 |
| 52-Week Range | 2.81 - 10.81 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 11.50 (+14.66%) |
| Earnings Date | May 18, 2026 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price target is $11.5, which is an increase of 14.66% from the latest price.
News
Alpha Tau reports Q1 EPS (12c), consensus (12c)
“The first quarter of 2026 has been a truly defining period for Alpha Tau (DRTS), reflecting the convergence of two powerful dynamics that have been years in the making: the…
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of pat...
Alpha Tau Medical Earnings release: Q1 2026
Alpha Tau Medical released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Alpha Tau Medical Ltd options imply 16.0% move in share price post-earnings
Pre-earnings options volume in Alpha Tau (DRTS) Medical Ltd is 1.7x normal with calls leading puts 14:1. Implied volatility suggests the market is anticipating a move near 16.0%, or 0c,…
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, to...
Alpha Tau price target raised to $14 from $12 at Ladenburg
Ladenburg raised the firm’s price target on Alpha Tau (DRTS) to $14 from $12 and keeps a Buy rating on the shares after the company announced interim results from the…
Alpha Tau price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alpha Tau (DRTS) to $15 from $12 and keeps a Buy rating on the shares. The firm added potential sales of Alpha…
Alpha Tau Medical Transcript: Study result
Alpha DaRT demonstrated strong safety and efficacy in the first three recurrent GBM patients, with two complete responses and one significant tumor reduction. Adverse events were manageable, and the approach enables precise, localized treatment with potential for re-treatment and broad applicability.
Alpha Tau Medical Press release: Study result
Alpha Tau Medical issued a press release on May 11, 2026, disclosing material business information to investors.
Alpha Tau Medical Slides: Study result
Alpha Tau Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Alpha Tau announces interim data from REGAIN trial
Alpha Tau (DRTS) announced interim data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma, also known as the REGAIN trial. In accordance with the FDA’s request…
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since ...
Alpha Tau completes enrollment in ReSTART trial
Alpha Tau (DRTS) announced the completion of enrollment in its ReSTART pivotal trial, a U.S. multicenter study evaluating the efficacy and safety of intratumoral Alpha DaRT for the treatment of…
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® to...
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA ...
Alpha Tau treats first patient with Alpha DaRT in Italy
Alpha Tau (DRTS) announced the treatment of the first patient in Italy in its feasibility and safety study of intratumoral diffusing alpha-emitter radiation for locally advanced pancreatic cancer. The...
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute
First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of Verona The study is the first ...
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT®
Alpha Tau presents updated results from two clinical trials of Alpha DaRT
Alpha Tau (DRTS) announced the presentation of updated pooled results from two first-in-human clinical trials of Alpha DaRT in pancreatic ductal adenocarcinoma at Digestive Disease Week. The results w...
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership
AUSTIN, Texas & CHARLESTON, S.C.--(BUSINESS WIRE)--The Medical University of South Carolina (MUSC), a nationally leading academic health system with a growing innovation ecosystem, today announced a s...
Alpha Tau Medical Registration statement: Registration filing
Alpha Tau Medical filed a registration statement on April 28, 2026, providing details about a securities offering with the SEC.
Alpha Tau files $300M mixed securities shelf
06:12 EDT Alpha Tau (DRTS) files $300M mixed securities shelf
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world's largest and most prestigious medical oncology conference - - Pooled analysis combines safety and ef...
Alpha Tau gets FDA investigational device exemption supplement to IMPACT study
Alpha Tau (DRTS) announced that the FDA has approved an investigational device exemption supplement to its U.S. multi-center pancreatic cancer pilot study, known as IMPACT, evaluating the safety, feas...